MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Olesoxime

CAS No. : 22033-87-0

MCE 站：Olesoxime

产品活性：Olesoxime (TRO 19622) 是一种靶向线粒体的神经保护性试剂，促进细胞存活，EC₅₀ 为 3.2±0.2 ?M。

研究领域：Metabolic Enzyme/Protease

作用靶点：Mitochondrial Metabolism

In Vitro: Exposure to Olesoxime (TRO 19622) (ranging from 0.1 to 10 ?M) at 1 h after plating significantly protects primary embryonic rat spinal MNs (that had been cultured for 3 days without brain-derived, ciliary and glia-derived neurotrophic factors) from cell death. At a concentration of 10 ?M, Olesoxime (TRO 19622) maintains survival of 74±10% of the neurons supported by a combination of neurotrophic factors (brain-derived, ciliary and glia-derived neurotrophic factors). The mean EC₅₀ in this assay is 3.2±0.2 ?M. In addition to preserving MN cell bodies, Olesoxime (TRO 19622) also promotes the outgrowth of neurites. At a concentration of 1 ?M, which increases cell survival by only 38%, Olesoxime (TRO 19622) increases overall neurite outgrowth per cell by 54%. Olesoxime (TRO 19622) belongs to a new family of cholesterol-oximes identified for its survival-promoting activity on purified motor neurons deprived of neurotrophic factors. Olesoxime (TRO 19622) targets proteins of the outer mitochondrial membrane, concentrates at the mitochondria and prevents permeability transition pore opening mediated by, among other things, oxidative stress.

In Vivo: Daily administration of Olesoxime (TRO 19622) (3 or 30 mg/kg sc) to adult mice for more than 2 months is well tolerated without toxicity or adverse effects. When animals are treated orally for 5 days following the lesion, Olesoxime (TRO 19622) increases motor neuron cell body survival in a dose-dependent manner with significant rescue at the highest dose of 100 mg/kg. At this dose, motor neuron survival is 29 ±2% (n=18) corresponding to a 42% increase in survival compared with vehicle-treated animals. Paclitaxel-treated rats that receive prophylactic treatment with 3 mg/kg/d or 30 mg/kg/d Olesoxime (TRO 19622) have 239±17.6 and 247±14.4 IENFs per cm, respectively. For both doses, the decreases are significantly less than the 46% decrease seen in the Paclitaxel-treated rats administered vehicle. However, both doses produce decreases (25% and 22%) that are significantly different relative to the na?ve control group.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  Stem Cell Signaling Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Glutamine Metabolism Compound Library  |  Neuroprotective Compound Library  |  CCCP  |  Rote  |  FCCP  |  (-)-Epigallocatechin Gallate  |  Mito-TEMPO  |  UK-5099  |  Lonidamine  |  Daidzin  |  Mitochonic acid 5  |  NIM811  |  Fumarate hydratase-IN-1  |  7ACC2  |  BAM 15  |  MPP+ iodide  |  α-Lipoic Acid  |  CTPI-2  |  L-2-Hydroxyglutaric acid disodium  |  L-Histidine  |  Ru360  |  MSDC 0160  |  Lipoic acid  |  Schaftoside  |  BI-6C9  |  Adjudin  |  Tempo  |  ER-000444793  |  Antimycin A1  |  Thiabendazole  |  KL1333  |  HQNO

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。